Pharmaron Beijing Co Ltd
SZSE:300759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
SZSE:300759
Watchlist
Price: 26.72 CNY -5.85% Market Closed
Market Cap: 39.7B CNY
Have any thoughts about
Pharmaron Beijing Co Ltd?
Write Note

Pharmaron Beijing Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharmaron Beijing Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Pharmaron Beijing Co Ltd
SZSE:300759
Gross Profit
ÂĄ3.8B
CAGR 3-Years
19%
CAGR 5-Years
30%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Gross Profit
ÂĄ15.4B
CAGR 3-Years
27%
CAGR 5-Years
29%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Gross Profit
ÂĄ6.6B
CAGR 3-Years
18%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Gross Profit
ÂĄ2.5B
CAGR 3-Years
8%
CAGR 5-Years
15%
CAGR 10-Years
26%
M
MGI Tech Co Ltd
SSE:688114
Gross Profit
ÂĄ1.5B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Gross Profit
ÂĄ559.6m
CAGR 3-Years
310%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharmaron Beijing Co Ltd
Glance View

Market Cap
39.7B CNY
Industry
Life Sciences Tools & Services

Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing and currently employs 14,923 full-time employees. The company went IPO on 2019-01-28. Pharmaron Beijing Co., Ltd. is a China-based company that provides research and manufacturing services throughout the discovery, development and manufacturing spectrum for small molecule drugs, cell therapies and gene therapies as well as providing testing services for medical devices and clinic research. The firm has four segments. The Laboratory Services segment includes laboratory chemistry, drug metabolism and pharmacokinetics/absorption, distribution, metabolism and excretion, biology, safety assessment and discovery of biologics services. The Clinical Development Services segment includes clinical research, site management organization, regulatory bioanalysis and radiolabelled sciences service. The Chemistry, Manufactory and Control Services segment includes process development and manufacturing, material science/pre-formulation, formulation development and manufacturing and analytical development and commercial manufacturing services. The firm also operates Others segment.

Intrinsic Value
36.55 CNY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Pharmaron Beijing Co Ltd's Gross Profit?
Gross Profit
3.8B CNY

Based on the financial report for Jun 30, 2024, Pharmaron Beijing Co Ltd's Gross Profit amounts to 3.8B CNY.

What is Pharmaron Beijing Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
30%

Over the last year, the Gross Profit growth was -7%. The average annual Gross Profit growth rates for Pharmaron Beijing Co Ltd have been 19% over the past three years , 30% over the past five years .

Back to Top